|
|
Article: Highlights from the 2007 American Academy of Neurology meeting.(news)(Conference news)
- Article from:
- Inside MS
- Article date:
- August 1, 2007
CopyrightCOPYRIGHT 2007 National Multiple Sclerosis Society. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
More than 10,000 practicing neurologists and researchers from around the world gathered at the 59th annual meeting of the American Academy of Neurology in Boston in April. Well over 200 MS-related presentations were made, many involving researchers funded by the National MS Society.
Follow-up studies of approved therapies Researchers reported on a follow-up to the BENEFIT study, in which treatment with Betaseron (interferon beta-1b, Bayer HealthCare Pharmaceuticals) delayed onset of clinically definite MS in people at high risk for the disease compared with people who did not receive treatment. In the follow-up study, both groups are now receiving Betaseron. The ...